文献速递肝病

卡维地洛联合核苷(酸)类似物治疗病毒学抑制的HBV代偿性肝硬化患者:一项随机开放标签试验

Carvedilol Plus NUC for Patients With HBV-Compensated Cirrhosis Under Virological Suppression: A Randomized Open-Label Trial.
PubMed 文献 · Am J Gastroenterol · 2023-11-06

该随机开放标签试验纳入238例病毒学抑制的HBV代偿性肝硬化合并小/中食管静脉曲张患者,1:1分配接受核苷(酸)类似物(NUC)单药或卡维地洛12.5 mg联合NUC治疗,随访2年。主要终点食管静脉曲张进展率在两组间无统计学显著差异(15.5% vs 12.7%,RR=0.79,95%CI 0.36-1.75,P=0.567);中食管静脉曲张亚组联合治疗促进静脉曲张消退更有利(43.5% vs 13.1%,P=0.022)。

要点

  • 卡维地洛联合NUC组2年食管静脉曲张进展率为12.7%,NUC单药组为15.5%,差异无统计学显著(P=0.567)。
  • 中食管静脉曲张亚组联合治疗组静脉曲张消退率43.5%,高于NUC单药组13.1%(P=0.022)。
  • 2年内肝脏相关事件(失代偿、肝细胞癌或死亡/肝移植)发生率两组相似(11.2% vs 10.4%,P=0.881)。

核心结论

  • 总体结果未显示加用卡维地洛策略与NUC单药在预防病毒学抑制的HBV代偿性肝硬化患者食管静脉曲张进展方面存在统计学显著差异。
  • 加用卡维地洛的方案可能对中食管静脉曲张患者提供更好的结局。

研究设计与样本

  • 随机对照开放标签试验,纳入病毒学抑制的HBV代偿性肝硬化合并小/中食管静脉曲张患者。
  • 共238例患者(小食管静脉曲张占77.3%)按1:1随机分配至NUC组(119例)或卡维地洛12.5 mg联合NUC组(119例)。
  • 205例患者(86.1%)完成配对内镜检查。
  • 主要终点为随访2年时食管静脉曲张的进展率。

主要发现

  • 食管静脉曲张进展率:NUC组15.5%(16/103) vs 卡维地洛联合NUC组12.7%(13/102),相对危险度=0.79,95%CI 0.36-1.75,P=0.567。
  • 中食管静脉曲张亚组分析显示卡维地洛联合NUC组促进静脉曲张消退的效果更有利(43.5% vs 13.1%,P=0.022),小食管静脉曲张亚组未见此效果(P=0.534)。
  • 2年内肝脏相关事件(失代偿、肝细胞癌或死亡/肝移植)发生率两组相似(11.2% vs 10.4%,P=0.881)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Portal hypertension progression can be relieved after controlling the etiology of liver cirrhosis. Whether beta-blockers could additionally enhance the effects during treatment, particularly for small esophageal varices (EV), was unclear. This study aims to assess the efficacy of add-on carvedilol to delay EV progression during anti-hepatitis B virus (HBV) treatment in HBV-related cirrhosis. METHODS: This randomized controlled trial enrolled patients with virologically suppressed HBV-compensated cirrhosis and small/medium EV. The participants were randomly assigned to receive nucleos(t)ide analog (NUC) or carvedilol 12.5 mg plus NUC (1:1 allocation ratio). The primary end point was the progression rate of EV at 2 years of follow-up. RESULTS: A total of 238 patients (small EV, 77.3%) were randomized into 119 NUC and 119 carvedilol plus NUC (carvedilol [CARV] combination group). Among them, 205 patients (86.1%) completed paired endoscopies. EV progression rate was 15.5% (16/103) in the NUC group and 12.7% (13/102) in the CARV combination group (relative risk = 0.79, 95% confidence interval 0.36-1.75, P = 0.567). Subgroup analysis on medium EV showed the CARV combination group had a more favorable effect in promoting EV regression (43.5% vs 13.1%, P = 0.022) than NUC alone, but not in small cases ( P = 0.534). The incidence of liver-related events (decompensation, hepatocellular carcinoma, or death/liver transplantation) within 2 years was similar between the 2 groups (11.2% vs 10.4%, P = 0.881). DISCUSSION: The overall results did not show statistically significant differences between the added carvedilol strategy and NUC monotherapy in preventing EV progression in patients with virologically suppressed HBV-compensated cirrhosis. However, the carvedilol-added approach might offer improved outcomes specifically for patients with medium EV (NCT03736265).

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Wang B, Zhou J, Wu X, et al. Carvedilol Plus NUC for Patients With HBV-Compensated Cirrhosis Under Virological Suppression: A Randomized Open-Label Trial. Am J Gastroenterol. 2023. PMID: 37929952. doi:10.14309/ajg.0000000000002569

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。